bioethics: Case Discussion Welcome

[bioethics@hsphsun2.harvard.edu]

>After a long hiatus I would like to welcome you again to the next session
>of the Ethical Issues in International Health Research Discussion List,
>sponsored by the Harvard School of Public Health.
>
>For the next four weeks, our discussion will focus on ethical issues in
>research and treatment.  Every two weeks a brief introduction and case
>study will be posted to the
>group along with questions to initiate discussion.  The dialogue for each
>case will continue for two weeks.
>
>Depending on the volume of responses, messages will either be posted to the
>discussion list individually or grouped by topic.  Participants are invited
>to contribute their own case studies and ethical questions for discussion,
>and we welcome information regarding relevant background readings and web
>resources as well.  These contributions may be e-mailed at any time
>to  bioethics@hsphsun2.harvard.edu and they will be posted during the
>appropriate week (according to topic).
>
>Before we begin, however, there is some essential information you will need:
>To post a message to the discussion (or if you have any questions or
>comments for the moderator), please send your e-mail message 
>to:bioethics@hsphsun2.harvard.edu.
>
>Also, the entire 4-week session will be archived and can be viewed at
>http://www.hsph.harvard.edu/bioethics/archives/>http://www.hsph.harvard.
>edu/bioethics/archives/
>
>The schedule is as follows:
>Case 1 (November 10-21) -- Double Standard of an AIDS Drug*
>
>Case 2 (November 24-December 5) -- HIV Vaccine Trials and Antiretroviral
>Therapy*

>*This case contributed by Julie Milstein at the University of Maryland
>School of Medicine Center for Vaccine Development
>
>
>Please note:  This is a moderated list, which means that messages will be
>reviewed prior to being posted to ensure that comments are relevant to the
>topic at hand.  This list is designed to provide participants with a forum
>for open dialogue concerning selected ethical issues in international
>health research.  We encourage productive exchange between all participants
>and ask that participants be respectful of other points of view.
>
>Thank you for your interest the first case study will arrive shortly.  We
>look forward to your participation and to an educational and productive set
>of discussions.